Inhibition of angiogenesis by the poly(ADP-ribose) polymerase inhibitor PJ-34

Anastasia Pyriochou, Gabor Olah, Edwin A. Deitch, Csaba Szabo, Andreas Papapetropoulos

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Angiogenesis-related treatments have a broad spectrum of potential applications ranging from cancer to macular degeneration, to wound healing. Thus, the identification of pharmacological agents that modulate new blood vessel formation has attracted much attention. In the present study, we investigated the effects of the poly(ADP-ribose) polymerase (PARP) inhibitor PJ-34 [N-(6-Oxo-5,6-dihydro-phenanthridin -2-yl)-N,N-dimethylacetamide] on angiogenesis. Treatment of chicken chorioallantoic membranes (CAM) with PJ-34 reduced vascular length in these tissues; paradoxically, lower doses of PJ-34 (0.03 or 0.3 nmol/ cm2) were more effective in inhibiting neovascularisation than higher doses (3 or 30 nmol/cm2). In vitro, incubation of endothelial cells (EC) with PJ-34 (300 nM to 10 μM) inhibited their proliferation in a concentration-dependent manner with maximal inhibition of 22.3% being observed at 10 μM. Capillary morphogenesis of EC grown on Matrigel was also negatively affected by PJ-34. In addition, PJ-34 abolished the migratory response to the prototype angiogenic factor vascular endothelial growth factor (VEGF) and reduced VEGF-stimulated activation of members of the mitogen activated protein kinase family (ERK1/2, p38), as well as Akt. PJ-34 also inhibited VEGF-induced NO release and cGMP accumulation. In conclusion, we provide evidence that PARP inhibition blocks angiogenesis-related EC properties by interfering with multiple signalling pathways leading to the inhibition of new blood vessel formation.

Original languageEnglish (US)
Pages (from-to)113-118
Number of pages6
JournalInternational Journal of Molecular Medicine
Volume22
Issue number1
StatePublished - Jul 2008
Externally publishedYes

Fingerprint

Vascular Endothelial Growth Factor A
Blood Vessels
Endothelial Cells
Chorioallantoic Membrane
Poly(ADP-ribose) Polymerases
Angiogenesis Inducing Agents
Macular Degeneration
Poly(ADP-ribose) Polymerase Inhibitors
N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride
Mitogen-Activated Protein Kinases
Morphogenesis
Wound Healing
Chickens
Pharmacology
Neoplasms
dimethylacetamide
matrigel
In Vitro Techniques

Keywords

  • Angiogenesis
  • Poly(ADP-ribose)
  • Polymerase inhibitor

ASJC Scopus subject areas

  • Genetics

Cite this

Inhibition of angiogenesis by the poly(ADP-ribose) polymerase inhibitor PJ-34. / Pyriochou, Anastasia; Olah, Gabor; Deitch, Edwin A.; Szabo, Csaba; Papapetropoulos, Andreas.

In: International Journal of Molecular Medicine, Vol. 22, No. 1, 07.2008, p. 113-118.

Research output: Contribution to journalArticle

@article{3afb5656f60c4dfd86bfcda77ec1a947,
title = "Inhibition of angiogenesis by the poly(ADP-ribose) polymerase inhibitor PJ-34",
abstract = "Angiogenesis-related treatments have a broad spectrum of potential applications ranging from cancer to macular degeneration, to wound healing. Thus, the identification of pharmacological agents that modulate new blood vessel formation has attracted much attention. In the present study, we investigated the effects of the poly(ADP-ribose) polymerase (PARP) inhibitor PJ-34 [N-(6-Oxo-5,6-dihydro-phenanthridin -2-yl)-N,N-dimethylacetamide] on angiogenesis. Treatment of chicken chorioallantoic membranes (CAM) with PJ-34 reduced vascular length in these tissues; paradoxically, lower doses of PJ-34 (0.03 or 0.3 nmol/ cm2) were more effective in inhibiting neovascularisation than higher doses (3 or 30 nmol/cm2). In vitro, incubation of endothelial cells (EC) with PJ-34 (300 nM to 10 μM) inhibited their proliferation in a concentration-dependent manner with maximal inhibition of 22.3{\%} being observed at 10 μM. Capillary morphogenesis of EC grown on Matrigel was also negatively affected by PJ-34. In addition, PJ-34 abolished the migratory response to the prototype angiogenic factor vascular endothelial growth factor (VEGF) and reduced VEGF-stimulated activation of members of the mitogen activated protein kinase family (ERK1/2, p38), as well as Akt. PJ-34 also inhibited VEGF-induced NO release and cGMP accumulation. In conclusion, we provide evidence that PARP inhibition blocks angiogenesis-related EC properties by interfering with multiple signalling pathways leading to the inhibition of new blood vessel formation.",
keywords = "Angiogenesis, Poly(ADP-ribose), Polymerase inhibitor",
author = "Anastasia Pyriochou and Gabor Olah and Deitch, {Edwin A.} and Csaba Szabo and Andreas Papapetropoulos",
year = "2008",
month = "7",
language = "English (US)",
volume = "22",
pages = "113--118",
journal = "International Journal of Molecular Medicine",
issn = "1107-3756",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Inhibition of angiogenesis by the poly(ADP-ribose) polymerase inhibitor PJ-34

AU - Pyriochou, Anastasia

AU - Olah, Gabor

AU - Deitch, Edwin A.

AU - Szabo, Csaba

AU - Papapetropoulos, Andreas

PY - 2008/7

Y1 - 2008/7

N2 - Angiogenesis-related treatments have a broad spectrum of potential applications ranging from cancer to macular degeneration, to wound healing. Thus, the identification of pharmacological agents that modulate new blood vessel formation has attracted much attention. In the present study, we investigated the effects of the poly(ADP-ribose) polymerase (PARP) inhibitor PJ-34 [N-(6-Oxo-5,6-dihydro-phenanthridin -2-yl)-N,N-dimethylacetamide] on angiogenesis. Treatment of chicken chorioallantoic membranes (CAM) with PJ-34 reduced vascular length in these tissues; paradoxically, lower doses of PJ-34 (0.03 or 0.3 nmol/ cm2) were more effective in inhibiting neovascularisation than higher doses (3 or 30 nmol/cm2). In vitro, incubation of endothelial cells (EC) with PJ-34 (300 nM to 10 μM) inhibited their proliferation in a concentration-dependent manner with maximal inhibition of 22.3% being observed at 10 μM. Capillary morphogenesis of EC grown on Matrigel was also negatively affected by PJ-34. In addition, PJ-34 abolished the migratory response to the prototype angiogenic factor vascular endothelial growth factor (VEGF) and reduced VEGF-stimulated activation of members of the mitogen activated protein kinase family (ERK1/2, p38), as well as Akt. PJ-34 also inhibited VEGF-induced NO release and cGMP accumulation. In conclusion, we provide evidence that PARP inhibition blocks angiogenesis-related EC properties by interfering with multiple signalling pathways leading to the inhibition of new blood vessel formation.

AB - Angiogenesis-related treatments have a broad spectrum of potential applications ranging from cancer to macular degeneration, to wound healing. Thus, the identification of pharmacological agents that modulate new blood vessel formation has attracted much attention. In the present study, we investigated the effects of the poly(ADP-ribose) polymerase (PARP) inhibitor PJ-34 [N-(6-Oxo-5,6-dihydro-phenanthridin -2-yl)-N,N-dimethylacetamide] on angiogenesis. Treatment of chicken chorioallantoic membranes (CAM) with PJ-34 reduced vascular length in these tissues; paradoxically, lower doses of PJ-34 (0.03 or 0.3 nmol/ cm2) were more effective in inhibiting neovascularisation than higher doses (3 or 30 nmol/cm2). In vitro, incubation of endothelial cells (EC) with PJ-34 (300 nM to 10 μM) inhibited their proliferation in a concentration-dependent manner with maximal inhibition of 22.3% being observed at 10 μM. Capillary morphogenesis of EC grown on Matrigel was also negatively affected by PJ-34. In addition, PJ-34 abolished the migratory response to the prototype angiogenic factor vascular endothelial growth factor (VEGF) and reduced VEGF-stimulated activation of members of the mitogen activated protein kinase family (ERK1/2, p38), as well as Akt. PJ-34 also inhibited VEGF-induced NO release and cGMP accumulation. In conclusion, we provide evidence that PARP inhibition blocks angiogenesis-related EC properties by interfering with multiple signalling pathways leading to the inhibition of new blood vessel formation.

KW - Angiogenesis

KW - Poly(ADP-ribose)

KW - Polymerase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=46749119301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46749119301&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 113

EP - 118

JO - International Journal of Molecular Medicine

JF - International Journal of Molecular Medicine

SN - 1107-3756

IS - 1

ER -